New prostate drug candidate put to the test in healthy volunteers
NCT ID NCT07643233
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial will compare a new drug called AJU-G721 to an existing reference drug, G721R, in 36 healthy adult men. The goal is to see if the two drugs produce similar levels in the blood and have comparable safety. Both drugs contain tamsulosin, which is used to treat symptoms of an enlarged prostate.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Tamsulosin (in AJU-G721 and G721R)
- What this could lead to
- If successful, this could confirm that AJU-G721 works the same as the reference drug, potentially offering a new treatment option for enlarged prostate.
- What could go wrong
- This is an early Phase 1 study in only 36 healthy men, not patients. It only checks drug levels and safety, not whether it actually helps BPH symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MODERATE-TO-SEVERE BENIGN PROSTATIC HYPERPLASIA (BPH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Bumin Hospital
Seoul, South Korea
More trials for these conditions
Other studies related to the condition(s) this trial covers.